Shares of Radius Health Inc. (NASDAQ:RDUS) fell 3.8% on Tuesday . The stock traded as low as $53.59 and last traded at $55.51, with a volume of 1,726,947 shares. The stock had previously closed at $57.72.

Several brokerages have recently weighed in on RDUS. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, May 2nd. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a research report on Tuesday, May 31st. Cowen and Company began coverage on shares of Radius Health in a research report on Friday, May 6th. They set an “outperform” rating for the company. Jefferies Group restated a “hold” rating on shares of Radius Health in a research report on Friday, August 5th. Finally, HC Wainwright started coverage on shares of Radius Health in a report on Monday, May 23rd. They issued a “buy” rating and a $55.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $61.73.

The stock’s 50-day moving average is $45.22 and its 200 day moving average is $36.54. The stock’s market cap is $2.40 billion.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same quarter in the prior year, the company earned ($0.61) EPS. Equities analysts anticipate that Radius Health Inc. will post ($4.19) earnings per share for the current fiscal year.

A number of large investors recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new stake in Radius Health during the fourth quarter worth approximately $1,362,000. New York State Common Retirement Fund increased its stake in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock worth $4,249,000 after buying an additional 18,259 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock worth $25,984,000 after buying an additional 29,601 shares during the period.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.